ZEVRA THERAPEUTICS, INC.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | Other Information |
|---|
(a) Disclosure in lieu of reporting on a Current Report on Form8-K.
None.
(b) Material changes to the procedures by which security holders* may*recommend nominees to the board of directors.
None.
(c) Insider Trading Arrangements and Policies.
On* March 21, 2025,Neil F. McFarlane, President and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 125,125 shares of the Company’s common stock until* March 19, 2026.*
On* March 26, 2025,Adrian W. Quartel, Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 79,533 shares of the Company’s common stock until March 31, 2026.*
On* March 27, 2025,R. LaDuane Clifton, Chief Financial Officer and Treasurer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 14,000 shares of the Company’s common stock until* March 31, 2026.*
On* March 27, 2025,Joshua Schafer, Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 13,875 shares of the Company’s common stock until* March 31, 2026.*
On* March 27, 2025,Rahsaan Thompson, Chief Legal Officer, Secretary, and Compliance Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 28,080 shares of the Company’s common stock until* March 31, 2026.*
On* March 27, 2025,Timothy J. Sangiovanni, Senior Vice President, Finance and Corporate Controller, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 4,750 shares of the Company’s common stock until* March 31, 2026.*
Other than as disclosed above, during thethree months ended* March 31, 2025,* no director or officer of the Company adopted or terminated a “Rule10b5-1 trading arrangement” or “non-Rule10b5-1 trading arrangement,” as each term is defined in Item408(a) of Regulation S-K.
39
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.